These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 19340897)

  • 1. Clostridium difficile associated infection, diarrhea and colitis.
    Hookman P; Barkin JS
    World J Gastroenterol; 2009 Apr; 15(13):1554-80. PubMed ID: 19340897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clostridium difficile infection: clinical spectrum and approach to management.
    Vaishnavi C
    Indian J Gastroenterol; 2011 Dec; 30(6):245-54. PubMed ID: 22183580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clostridium difficile-associated diarrhea and colitis.
    Gerding DN; Johnson S; Peterson LR; Mulligan ME; Silva J
    Infect Control Hosp Epidemiol; 1995 Aug; 16(8):459-77. PubMed ID: 7594392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clostridium difficile and the disease it causes.
    Norén T
    Methods Mol Biol; 2010; 646():9-35. PubMed ID: 20597000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population.
    Mezoff E; Mann EA; Hart KW; Lindsell CJ; Cohen MB
    J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):437-41. PubMed ID: 21407116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred fluoroquinolones.
    Walbrown MA; Aspinall SL; Bayliss NK; Stone RA; Cunningham F; Squier CL; Good CB
    J Manag Care Pharm; 2008; 14(1):34-40. PubMed ID: 18240880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAP1 strain type predicts outcomes from Clostridium difficile infection.
    See I; Mu Y; Cohen J; Beldavs ZG; Winston LG; Dumyati G; Holzbauer S; Dunn J; Farley MM; Lyons C; Johnston H; Phipps E; Perlmutter R; Anderson L; Gerding DN; Lessa FC
    Clin Infect Dis; 2014 May; 58(10):1394-400. PubMed ID: 24604900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characteristics of Clostridium difficile infection in a high complexity hospital and report of the circulation of the NAP1/027 hypervirulent strain in Colombia].
    Gualtero SM; Abril LA; Camelo N; Sanchez SD; Davila FA; Arias G; Silva E; Bustos IG; Josa DF; Torres IC; Zambrano LC; Pareja MJ
    Biomedica; 2017 Dec; 37(4):466-472. PubMed ID: 29373767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating antibody and memory B-Cell responses to C. difficile toxins A and B in patients with C. difficile-associated diarrhoea, inflammatory bowel disease and cystic fibrosis.
    Monaghan TM; Robins A; Knox A; Sewell HF; Mahida YR
    PLoS One; 2013; 8(9):e74452. PubMed ID: 24058568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bench-to-bedside review: Clostridium difficile colitis.
    Gould CV; McDonald LC
    Crit Care; 2008; 12(1):203. PubMed ID: 18279531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new role for heat shock factor 27 in the pathophysiology of
    Yanda MK; Guggino WB; Cebotaru L
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G120-G129. PubMed ID: 31709831
    [No Abstract]   [Full Text] [Related]  

  • 12. Human intestinal enteroids as a model of
    Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
    Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
    [No Abstract]   [Full Text] [Related]  

  • 13. Polymerase chain reaction test for Clostridium difficile toxin B gene reveals similar prevalence rates in children with and without inflammatory bowel disease.
    Lamousé-Smith ES; Weber S; Rossi RF; Neinstedt LJ; Mosammaparast N; Sandora TJ; McAdam AJ; Bousvaros A
    J Pediatr Gastroenterol Nutr; 2013 Sep; 57(3):293-7. PubMed ID: 23698022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.
    Wieczorkiewicz JT; Lopansri BK; Cheknis A; Osmolski JR; Hecht DW; Gerding DN; Johnson S
    Antimicrob Agents Chemother; 2016 Jan; 60(1):418-23. PubMed ID: 26525793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence.
    Deshpande A; Pant C; Jain A; Fraser TG; Rolston DD
    Curr Med Res Opin; 2008 Feb; 24(2):329-33. PubMed ID: 18067688
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Bolukcu S; Hakyemez IN; Gultepe BS; Okay G; Durdu B; Koc MM; Aslan T
    Saudi J Gastroenterol; 2019; 25(6):384-389. PubMed ID: 31793457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease.
    Jen MH; Saxena S; Bottle A; Aylin P; Pollok RC
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1322-31. PubMed ID: 21517920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile.
    Drudy D; Harnedy N; Fanning S; Hannan M; Kyne L
    Infect Control Hosp Epidemiol; 2007 Aug; 28(8):932-40. PubMed ID: 17620240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies.
    Lamont JT
    Trans Am Clin Climatol Assoc; 2002; 113():167-80; discussion 180-1. PubMed ID: 12053708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of Clostridium difficile-associated disease in North America and Europe.
    Kuijper EJ; Coignard B; Tüll P; ; ;
    Clin Microbiol Infect; 2006 Oct; 12 Suppl 6():2-18. PubMed ID: 16965399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.